Please use this identifier to cite or link to this item: https://dspace.uzhnu.edu.ua/jspui/handle/lib/74190
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHorlenko, Olesya M.-
dc.contributor.authorHechko, Khrystyna A.-
dc.contributor.authorPrylypko, Lyubomyra B.-
dc.contributor.authorHechko, Mykhaylo M.-
dc.contributor.authorHorlenko, Fedir V.-
dc.contributor.authorGalay, Bohdan M.-
dc.contributor.authorГорленко, Олеся Михайлівна-
dc.contributor.authorГечко, Христина Андріївна-
dc.contributor.authorГорленко, Федор Вікторович-
dc.contributor.authorГечко, Михайло Михайлович-
dc.contributor.authorПрилипко, Любомира Богданівна-
dc.contributor.authorГалай, Богдан Михайлович-
dc.date.accessioned2025-06-01T12:05:12Z-
dc.date.available2025-06-01T12:05:12Z-
dc.date.issued2025-
dc.identifier.citationСomprehensive approach to comparative characteristics of clinical and laboratory parameters of the study in children - in 6 months after covid-19 treatment and 6 months after Covid-19 vaccination / O. M. Horlenko, Kh. A. Hechko, Lю B. Prylypko, M. M. Hechko, et al. Wiadomości Lekarskie Medical Advances. 2025. Vol. 78(4). P. 838-844.uk
dc.identifier.urihttps://dspace.uzhnu.edu.ua/jspui/handle/lib/74190-
dc.descriptiondoi: 10.36740/WLek/203895uk
dc.description.abstractAim: To study and analyze data on clinical and laboratory parameters of investigated children in 6 months after treatment and 6 months after Covid-19 vaccination. Materials and Methods: A prospective clinical and laboratory examination of a children group (group 1) with identified Covid-19 (n=68) was carried out in comparison with a group (n=31) of Covid-19 vaccinated children (group 2) after 6 months of observation. Results: The data of Anti-SARS-CoV-2-S1-RBD IgG, non-significant intergroup differences in levels were found (344.71 ± 87.62 versus 315.67 ± 74.91 BAU/ml, p=0.11). Significant differences were found in the children group who was 6 months after Covid-19 treatment and the control group, as well as in the group before and 6 months after Covid-19 vaccination, in the following parameters: IL-2 (p6<0.01; p7<0.01, with a prevalence of 6 and 4 times, respectively); IL-4 (p6<0.01; p7<0.01with a prevalence of 6 and 4.6 times, respectively), IL-10 (p6<0.01; p7<0.01 with a prevalence of 6 and 4.8 times, respectively), Procalcitonin (p6<0.01; p7<0.01, 18 times and 1.4 times respectively). Conclusions: In our study, according to the data of multivariate linear regression analysis, the level of Anti-SARS-CoV-2-S1-RBD IgG is the dependent variable, and D-dimer, Na level, Total Cholesterol, LF, IL-6, IgG are the influencing factors which determine the COVID-19 anti-infective protection.uk
dc.language.isoenuk
dc.relation.ispartofseriesWiadomości Lekarskie;-
dc.subjectCovid-19uk
dc.subjectvaccinationuk
dc.subjectclinical laboratory investigationuk
dc.subjectchildrenuk
dc.titleСomprehensive approach to comparative characteristics of clinical and laboratory parameters of the study in children - in 6 months after covid-19 treatment and 6 months after Covid-19 vaccinationuk
dc.typeTextuk
dc.pubTypeСтаттяuk
Appears in Collections:Наукові публікації кафедри терапії та сімейної медицини

Files in This Item:
File Description SizeFormat 
838.pdf184 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.